Literature DB >> 6138453

Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.

M Terai, S Usuda, I Kuroiwa, O Noshiro, H Maeno.   

Abstract

Effects of YM-09151-2 and five other neuroleptics (haloperidol, spiperone, chlorpromazine, sulpiride and clozapine) on the binding of [3H]-ligands to nine different receptors (alpha 1-adrenergic, alpha 2-adrenergic, beta-adrenergic, muscarinic, D2-dopaminergic, H1-histaminergic, 5HT1-serotonergic, 5HT2-serotonergic and opiate receptors) and on dopamine-sensitive adenylate cyclase were determined using brain membranes in the rat, guinea-pig and dog. The affinity of YM-09151-2 for D2-receptors with a Ki value of 0.1 nM was more than 1000-times higher than that for the other receptors and dopamine-sensitive adenylate cyclase, and it was the greatest among the neuroleptics tested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138453     DOI: 10.1254/jjp.33.749

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  12 in total

1.  The disruptive effects of ketamine on passive avoidance learning in mice: involvement of dopaminergic mechanism.

Authors:  Y Uchihashi; H Kuribara; Y Isa; T Morita; T Sato
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

2.  Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm Gen Sect       Date:  1990

3.  Characterization of [3H]nemonapride binding to mouse brain dopamine D2 receptors assessed in vivo and ex vivo for metabolic modeling in PET studies.

Authors:  K Ishiwata; K Inami; T Sasaki; T Nozaki; M Senda
Journal:  J Neural Transm Gen Sect       Date:  1994

4.  Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.

Authors:  H B Niznik; D E Grigoriadis; I Pri-Bar; O Buchman; P Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

5.  Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity.

Authors:  J Arnt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

6.  Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization.

Authors:  H Ujike; T Onoue; K Akiyama; T Hamamura; S Otsuki
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Studies on YM-12617: a selective and potent antagonist of postsynaptic alpha 1-adrenoceptors.

Authors:  K Honda; T Takenaka; A Miyata-Osawa; M Terai; K Shiono
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

8.  Inhibition of methamphetamine sensitization by post-methamphetamine treatment with SCH 23390 or haloperidol.

Authors:  H Kuribara
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

9.  Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats.

Authors:  F Wanibuchi; S Usuda
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Caffeine enhances the stimulant effect of methamphetamine, but may not affect induction of methamphetamine sensitization of ambulation in mice.

Authors:  H Kuribara
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.